Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Jennifer R. Brown et al.|New England Journal of Medicine|2014Cited by 1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A. Burger, Thomas J. Kipps, Alessandra Tedeschi et al.|New England Journal of Medicine|2015Cited by 1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Bonnie K. Harrington et al.|New England Journal of Medicine|2015Cited by 890
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patternsAnna Schuh, David Bentley|Blood|2012Cited by 332
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, William G. Wierda, Barbara Eichhorst et al.|Journal of Clinical Oncology|2018Cited by 313